Has Insys Discovered The Acthar Killer?
Mallinckrodt has come under fire for Acthar’s high price. Acthar simply does not have much competition in treating infantile spasms. According to Shocking The Street, an investment service the Shock Exchange runs in conjunction with Seeking Alpha, that could soon change. Insys (INSY) has a proposed drug to treat infantile spasms. If approved it could cut market share or pricing for Acthar. This could make it difficult for Mallinckrodt to service its nearly $7 billion debt load and raise questions about its going concern value.